Platelet-activating factor: a potential therapeutic target to improve cancer immunotherapy.

Autor: Yan Q; Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Mohammadpour H; Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Jazyk: angličtina
Zdroj: Molecular oncology [Mol Oncol] 2024 Nov 19. Date of Electronic Publication: 2024 Nov 19.
DOI: 10.1002/1878-0261.13758
Abstrakt: The tumor microenvironment (TME) fosters cancer progression by supporting the differentiation and proliferation of myeloid-derived suppressor cells (MDSCs), which play a critical role in suppressing immune responses and facilitating tumor growth. Recent findings by Dahal et al. reveal that platelet-activating factor (PAF), a lipid mediator elevated in the TME, contributes to the differentiation of neutrophils into immunosuppressive neutrophils. They showed that inhibiting PAF signaling reduces MDSC-mediated immunosuppression, thereby enhancing cytotoxic T-cell activity. This approach may improve cancer immunotherapy outcomes, particularly when combined with checkpoint blockade therapies, suggesting a promising avenue for therapeutic development.
(© 2024 The Author(s). Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.)
Databáze: MEDLINE
Externí odkaz: